Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer.
C. J. Allegra
Consultant or Advisory Role - Genentech (U)
G. A. Yothers
Consultant or Advisory Role - Roche/Genentech (U)
M. J. O'Connell
Consultant or Advisory Role - Roche; Sanofi
S. Sharif
No relevant relationships to disclose
N. J. Petrelli
Consultant or Advisory Role - Genentech
L. H. Colangelo
No relevant relationships to disclose
N. Wolmark
Consultant or Advisory Role - Roche/Genentech (U)